December 12, 2019 09:18 AM ESTUpdated 09:47 AM

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line

John Carroll

Editor & Founder

Three days after Gilead’s Kite subsidiary showed off stellar data on their number 2 CAR-T KTE-X19 at ASH, the executive team has pivoted straight to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

On the heels of promis­ing MCL da­ta, Kite hus­tles its 2nd CAR-T to the FDA as the next big race in the field draws to the fin­ish line

Editor & Founder

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

On the heels of promising MCL data, Kite hustles its 2nd CAR-T to the FDA as the next big race in the field draws to the finish line